Bayer clears key US Supreme Court hurdle, shares trade steadily after surge

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 14:58.

Bayer (DE000BAY0017) is still digesting a pivotal US Supreme Court ruling on glyphosate in its Roundup herbicide portfolio. The DAX constituent trades in Germany on venues including Xetra and Stuttgart, with shares stabilizing after Thursday’s pronounced reaction to the court decision, according to market data and news reports.

What Reuters and dpa-AFX report

The hook for the Bayer stock this week is the decision in the Durnell case before the US Supreme Court, where the court sided with Bayer and rejected an appeal linked to Roundup litigation. According to reports from Deutsche Presse-Agentur and Dow Jones Newswires, Bayer described the ruling as helping to significantly contain ongoing glyphosate-related lawsuits in the United States.

German news services dpa-AFX and Spiegel emphasize that the ruling covers a specific Roundup dispute but carries signalling value for other cases, as it strengthens Bayer’s position on federal pre-emption and safety labeling arguments. In coverage summarized by MarketScreener, Bayer shares jumped to a roughly four-month high in Frankfurt trading after the Supreme Court outcome, illustrating how litigation headlines can move a large-cap healthcare and agriculture name.

Analyst reactions to the Supreme Court win

Analysts have reacted quickly to the court decision, framing it as at least a partial litigation overhang relief. Goldman Sachs reiterated its Buy rating on Bayer and confirmed a price target of 55 euros, according to MarketScreener’s aggregation of broker notes dated June 25. Goldman’s stance points to continued confidence in Bayer’s ability to navigate both pharmaceutical and crop science risks within its portfolio.

Separately, DZ Bank lifted its assessment of Bayer’s fair value, explicitly referring to the Supreme Court outcome as a “fundamental liberation strike” for the group’s balance sheet and risk profile, based on dpa-AFX analyst flash commentary summarized by finanzen.net. The DZ Bank note argues that a clearer litigation trajectory can help investors focus more on Bayer’s operating performance rather than legal uncertainty.

The business and products behind Bayer

Bayer generates its revenue primarily through three operating divisions: Pharmaceuticals, Consumer Health and Crop Science, each with distinct product portfolios and geographic exposures, according to company information and public filings. In pharmaceuticals, a key product in recent years has been Xarelto, an oral anticoagulant for the prevention and treatment of blood clots, while in crop science the group markets herbicides such as Roundup alongside seeds and digital farming solutions.

Where the Bayer shares trade today

The Bayer shares (DE000BAY0017) most recently traded on the Stuttgart exchange at around 47.06 euros as of 2026-06-26, 09:41, based on finanzen.net price data. This places the stock below the 55-euro level referenced in Goldman Sachs’ Buy rating, with the market continuing to weigh litigation developments against the operating outlook.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or a solicitation to engage in securities transactions. All data and assessments are based on sources indicated and may change over time.